Request Demo
Pharmaceutical Insights
Navigate pharmaceutical trends with our insights on targets, institutional pipelines, clinical advances, and new drugs.
Recent blog posts
Latest Hotspot
8 min read
NCT07630727 AHB-171 Hepatitis B, Chronic Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
23 July 2026
NCT07630727 clinical trial report covering AHB-171, Phase 2, endpoints, sponsor, geography, readout timing and development white space.
Latest Hotspot
8 min read
NCT07631052 Capecitabine ER-positive/HER2-negative Breast Cancer Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
23 July 2026
NCT07631052 clinical trial report covering Capecitabine, Phase 2, endpoints, sponsor, geography, readout timing and development white space.
Latest Hotspot
8 min read
NCT07630714 Anifrolumab-FNIA Systemic Lupus Erythematosus Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
23 July 2026
NCT07630714 clinical trial report covering Anifrolumab-FNIA, Phase 2, endpoints, sponsor, geography, readout timing and development white space.
Latest Hotspot
8 min read
NCT07630077 Trastuzumab Rezetecan Locally Advanced Lung Non-Small Cell Carcinoma Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
23 July 2026
NCT07630077 clinical trial report covering Trastuzumab Rezetecan, Phase 2, endpoints, sponsor, geography, readout timing and development white space.
Latest Hotspot
8 min read
NCT07629167 Doxycycline Hyclate Acneiform Eruptions Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
23 July 2026
NCT07629167 clinical trial report covering Doxycycline Hyclate, Phase 2, endpoints, sponsor, geography, readout timing and development white space.
Latest Hotspot
8 min read
NCT07631208 Teclistamab Lung Diseases, Interstitial Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
23 July 2026
NCT07631208 clinical trial report covering Teclistamab, Phase 2, endpoints, sponsor, geography, readout timing and development white space.
Latest Hotspot
8 min read
CTR20262203 FuFangQinlan Common Cold Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
23 July 2026
CTR20262203 clinical trial report covering FuFangQinlan, Phase 2, endpoints, sponsor, geography, readout timing and development white space.
Latest Hotspot
8 min read
CTR20262246 TAEST-16001 Locally Advanced Soft Tissue Sarcoma Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
23 July 2026
CTR20262246 clinical trial report covering TAEST-16001, Phase 2, endpoints, sponsor, geography, readout timing and development white space.
Latest Hotspot
8 min read
NCT07633288 Resomelagon Viral respiratory infection Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
23 July 2026
NCT07633288 clinical trial report covering Resomelagon, Phase 2, endpoints, sponsor, geography, readout timing and development white space.
Latest Hotspot
8 min read
NCT07632846 Roflumilast Rheumatoid Arthritis Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
23 July 2026
NCT07632846 clinical trial report covering Roflumilast, Phase 2, endpoints, sponsor, geography, readout timing and development white space.
Latest Hotspot
8 min read
NCT07632872 Desloratadine Rheumatoid Arthritis Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
23 July 2026
NCT07632872 clinical trial report covering Desloratadine, Phase 2, endpoints, sponsor, geography, readout timing and development white space.
Latest Hotspot
8 min read
NCT07632209 Anlotinib Dihydrochloride Extensive stage Small Cell Lung Cancer Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
23 July 2026
NCT07632209 clinical trial report covering Anlotinib Dihydrochloride, Phase 2, endpoints, sponsor, geography, readout timing and development white space.